Search clinical trials for: Influenza Virus Vaccines

Total 27390 results

GlaxoSmithKline

Completed

Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

India
MedImmune LLC

Completed

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Healthy

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States
University of Pittsburgh
Sanofi Pasteur, a Sanofi Company

Completed

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Influenza

United States
University of Massachusetts, Worcester
Pfizer; Reliant Medical Group

Completed

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

Influenza | Infections, Pneumococcal

United States
Green Cross Corporation

Completed

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

Influenza, Human

Korea, Republic of
Novartis Vaccines
Novartis

Completed

Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

Influenza

United States, Mexico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
Baylor College of Medicine
National Institute of Allergy and Infectious Diseases (NIAID); Novartis; Sanofi... and other collaborators

Completed

Control of Epidemic Influenza Through a School-based Influenza Vaccination Program (CEI)

Influenza

United States
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age

Hepatitis B | Pertussis | Tetanus | Diphtheria | Hemophilus Influenzae B

India
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b Infection

Korea, Republic of
Novartis Vaccines

Completed

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Influenza

Italy, Spain
Novartis
Novartis Vaccines

Withdrawn

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Influenza A Virus, H7N9 Subtype

United States
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

Seasonal Influenza

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

Influenza

Guatemala
National Institute of Allergy and Infectious Diseases...

Completed

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

Human Parainfluenza Virus 2

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Dermatitis, Atopic

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Novartis Vaccines
Novartis Vaccines and Diagnostics (formerly Chiron Vaccines)

Completed

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

Influenza Disease; Flu

United States
University of Colorado, Denver
University of Alabama at Birmingham; All India Institute of Medical Sciences... and other collaborators

Completed

Influenza Immunization of Children in India

Influenza

India
Novartis Vaccines

Completed

Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine

Novel Influenza A (H1N1) | A New Flu Virus of Swine Origin

Chile, Colombia, Germany, Switzerland
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

Influenza

Mexico
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
GlaxoSmithKline

Completed

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

Influenza

United States
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
Novartis Vaccines

Completed

Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008

Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Pre-pandemic Influenza Vaccine

Czech Republic
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines

Prophylaxis of Avian Influenza Vaccine

United Kingdom
Novartis Vaccines

Completed

Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study

FLU

Finland
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany

3

Subscribe